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1. Introduction
Is not this still the truth? Or, are we today, over 100 years after the first glioma operation, 
however, nearer to the option that we can treat, even cure, most of gliomas or at least keep the 
disease under control for very many years? The most frequent primary brain tumor, glioma, 
is still a nightmare for neurooncologists, neuropathologists, neurosurgeons, and other related 
professionals, but for patients and their families first of all.
If we look at the results of the papers published in the influential Medline database (accessed 
in December 2018), we will find a paper on glioma published back in 1870 [1]. For the next 
almost 150 years, in this base alone, we can find more than 87,000 papers on the same topic. 
On the other hand, in the same base only in the past 5 years, over 22,000 papers have been 
published having basically a story on gliomas (almost a quarter of all publications on glio-
mas). Does this mean that in the recent years the glioma field research has been more fruitful 
than ever before? Does this promise, or at least give hope, that we will find the way to put this 
serious disease under control?
In the USA, primary brain tumors account for about 2% of all cancers, with an overall annual 
incidence of 22 per 100,000 population, with nearly 80,000 new cases of which one-third will 
be malignant [2, 3].
The past three decades have been marked with huge enthusiasm of scientists’ and pro-
fessionals’ efforts to bring this serious disease into the context of curable or even cured 
one. Brain glioma patient treatment has significantly changed over time. Undoubtedly, the 
architect of this fight, Hurvey Chusing, early in the twentieth century, tried to solve the 
problem surgically and by tumor removal from the brain. History would very soon show 
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that there are brain tumors for which surgery is not sufficient; for some of them, it is not 
the first option or treatment at all. However, gliomas have remained in focus of interest 
not only of neurosurgeons but of oncologists, pathologists, neuroradiologists, forensics, 
and other related medical and nonmedical disciplines either. Not unimportant is also the 
 interest of pharmaceutical industry and researchers in the field of biomedical technologies 
in the glioma field.
2. Where we were
Expansion of new diagnostic modalities and glioma treatment, such as imaging, stereotaxic 
localization, and standardization of the microsurgical technique, practically started in the 
1980s. These methods, however, contributed to a better, safer, and more precise glioma resec-
tion, but there was no clear confirmation of better survival. We had to hope for better adjuvant 
therapy effects.
Until recently, rare were prospective randomized studies confirming that the gross total 
resection improved the outcome. The use of 5-ALA at resection enabled the doubling of time 
of 6-month progression free survival (PFS) and overall survival (OS). Significant glioma treat-
ment progress occurred with the introduction of neuronavigational (frameless) biopsy in 
almost routine practice, followed by analysis of a tumor sample with a series of biomarkers; 
so, even before entering the operating theater for tumor resection, now it is possible to have a 
lot of information on its nature; glioma resection can be worked out in much more detail both 
for low-grade glioma (LGG) and for high-grade glioma (HGG). We should have in mind that 
today’s accepted practice is that, when frozen section shows grade III glioma, we should do 
the aggressive tumor resection as much as possible. For grade IV (glioblastoma), the extensive 
resection is also critical for outcome [4]. On the other hand, midline tumors have a poorer 
prognosis compared to lobar equivalents, probably for the reason that the radical resection is 
feasible with more difficulties [5].
With time, significant progress has been made in the treatment and strategy of glioma 
patient treatment. This relates particularly to malignant gliomas. A shift has been made 
both in treatment and in diagnostic, with an accent on ever more powerful apparatus for 
neuroradiological scanning, magnetic resonance (MRI) first of all. Introduction of MRI in 
the late 1980s revolutionized management of intracranial tumors, and advanced neuro-
imaging today is one of the most important prerequisites for the modern treatment of 
glioma. This is possible especially because of combined use of contemporary radiologi-
cal modalities, particularly integration of structural, metabolic, and functional imaging, 
which provides optimal multifaceted information for detailed characterization of intracra-
nial gliomas [6]. Methods of the definite confirmation of the glioma kind and grade have 
walked a path from classical macro- and microscopic pathohistological confirmation of 
tumor, through morphological-histological, to molecular and genetic diagnosis practically 
accepted today.
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3. Where we are now
Brain glioma is infrequently also denoted as slowly growing neoplasm that is most often dis-
covered in younger adults, and it is presented with minimal symptoms or no such symptoms at 
all. The World Health Organization (WHO) classification system for glial tumors offered guide-
lines, which can predict the disease course; treatment modalities are thus recommended [7]. 
Nevertheless, these guidelines are based mostly on histological diagnosis. European Association 
for Neuro-Oncology (EANO) also presented its guidelines [8]. Yet, histologically the same tumors 
may have different courses, response to therapy and eventually to outcome. Molecular markers 
that carry both diagnostic and prognostic information add valuable tools by redefining tumor 
subtypes within each WHO category. That is why these molecular biomarkers have become an 
integral part of tumor assessment in modern neurooncology [9]. In that sense, markers such as 
biomarkers (IDH mutations, promoter methylation of MGMT, chromosomal deletion of 1p/19q, 
mutations of EGFR and ATRX genes, and BRAF fusion) can today guide clinicians to make bet-
ter decisions in some subtypes of gliomas, including anaplastic oligodendroglioma and GBM 
in the elderly [9, 10]. The integration of genome-wide data delineated three molecular classes of 
LGG, and we believe today that those without an IDH mutation were molecularly and clinically 
similar to GBM [11].
Significant progress has been made generally in glioma treatment with the use of modern 
radiotherapy ways and new chemotherapeutics. Several studies in the past decade have dealt 
with very promising temozolomide (TMZ) in glioma treatment. Baumert et al., in recently 
published randomized study results, have reported that they did not find any significant 
difference in outcome of the overall patient population treated with either radiotherapy alone 
or TMZ chemotherapy alone [12]. On the other hand, in the just published EORTC trial, ran-
domized controlled research on phase 2 published in Lancet, van den Bent et al. have found 
no evidence of improved overall survival with bevacizumab (Avastin) and TMZ combination 
treatment versus TMZ monotherapy in patients with first recurrence of WHO grades II and 
III glioma, without 1p/19q codeletion [13].
A new swing in glioma treatment was the defining of a molecular genetics signature, which 
can predict patient’s outcome with the loss of 1p and 19q in anaplastic oligodendroglioma. 
Specifically, such patients responded very well to procarbazine, cyclohexychloroethylnitro-
surea CCNU, and vincristine (PCV) chemotherapy or TMZ. When it comes to glioblastoma 
multiforme (GBM), hope was set on MGMT gene and its methylation [4].
Surgically, progress was made possible with the development and use of technological aids, first 
of all of neuronavigation, cortical mapping, electrocorticography, neuromonitoring, functional 
and intraoperative MRI, magnetoencephalography (MEG). As great hope was placed on exten-
sion of tumor resection, brain mapping in particular offered additional safety to the neurosur-
geon to provide as good result as possible with maximal and today popular supratotal resection.
The current paradigm shift considers glioma management in a comprehensive perspec-
tive that takes into account the intricate connectivity of the cerebral networks. Lesions 
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previously considered inoperable are today more accessible and safer for resection; the 
surgeon has greater self-confidence and better preoperative knowledge about the tumor 
and can expect better result of the glioma resection itself; and patients can expect a better 
outcome. This is particularly important for those lesions for which neurosurgical resection 
and the extent of resection (EOR) is still the most important part of treatment and standard 
of care [14–16].
To achieve as good result as possible, somatosensory evoked potentials (SSEPs), motor 
evoked potentials (MEPs), visual evoked potentials (VEPs), brainstem auditory evoked 
potentials (BAEPs), and electrocorticography (ECoG) are used nowadays routinely during 
glioma surgery. For brainstem gliomas, specific mapping with direct electrical stimulation 
(DES), corticobulbar tract MEP monitoring, and free-running electromyography (EMG) of 
the various muscles innervated by the cranial nerves are also required. Awake craniotomy 
and intraoperative mapping of language and sensorimotor functions with DES have become 
standard techniques for removal of cerebral neoplasms affecting eloquent cortical areas and 
subcortical pathways [17].
The present data provide prognostic information for patients with pilocytic astrocytoma and 
confirm that age and tumor size had a significant effect on OS [18]. For patients with anaplastic 
astrocytic gliomas, Nayak et al. [18] have found the median overall survival 2.9 years, and 1-year 
OS rate was 87%. Novel therapeutics is needed in patients with tumors not amenable to resec-
tion or radiosurgery [19]. The joint efforts of neuroscientists, researchers, and clinicians have 
provided an unprecedented ability to localize lesions and to assess the human brain function at 
the microscopic, mesoscopic, and macroscopic scales [14].
4. Where we are going
Treatments and better outcomes for primary brain tumors have long lagged behind those of 
other tumors. Rapid advances in neurooncology, cancer and CNS immunology, and progress 
in genomics have created more therapeutic opportunities than ever before [2, 3]. There is no 
doubt that significant changes have occurred in management of glioma patients. In the past 
three decades, we have led to the discovery of hundreds of molecular alterations in grades 
II, III, and IV gliomas. Among these molecular alterations, three are particularly noteworthy, 
because they occur early during glioma formation, are prevalent in glioma, or are strongly 
associated with overall survival. Codeletion of chromosome arms 1p and 19q (1p/19q codele-
tion), which is associated with the oligodendroglial histologic type and with sensitivity to 
chemotherapy with alkylating agents. The second was mutation in either IDH1 or IDH2 gene 
associated with a distinctive tumor cell metabolism. The third was mutation in the promoter 
of TERT, which is seen in both the most aggressive human glioma (grade IV astrocytoma) and 
the least aggressive diffuse human glioma (grade II oligodendroglioma) [11, 18].
Pamir and his group (2017) stated that molecular subsets in hemispheric diffuse gliomas 
result in different tumor biology and clinical behaviors [20]. Eckel-Passow et al. [21] pub-
lished significant study on a sample of 1081 gliomas, which they divided into five molecular 
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groups according to three alterations: mutations in the TERT promoter, mutations in IDH, 
and codeletion of chromosome arms 1p and 19q (Figure 1). They concluded that “the groups 
had different ages at onset, overall survival, and associations with germline variants, which 
implies that they are characterized by distinct mechanisms of pathogenesis” [21]. In favor of 
this, in the future, we should also incorporate alterations in ATRX, TP53, EGFR, or PTEN or 
other alterations that might be useful to consider in the diagnosis of glioma [11].
WHO grade I tumors and WHO grade II tumors should not be grouped together as low grade, 
because the two disease processes are markedly different. For patients with grade II glioma 
who had undergone subtotal tumor resection, Buckner and colleagues suggest combination of 
chemotherapy in addition to radiation therapy [22]. Opposite to the real low-grade lesions are, 
for example, dysembryoplastic neuroepithelial tumors are associated with continuous growth 
and inevitable malignant transformation. This fact supports the concept that grade II gliomas 
are premalignant and that the use of early aggressive surgical treatment is a very important 
part of their treatment pathway [18]. Al-Tamimi and Duffau’s group [23] suggest that after 
radical resection, the presence of foci of transformation within a background of grade II 
tumor does not necessarily require immediate adjuvant therapy. They suggest that a tailored 
approach should be used, taking into account the extent of resection, the full histopathologic 
and molecular profile of the tumor, and careful evaluation of the resection margins [15, 17, 23].
Speaking of high-grade glioma, despite the efforts made in research on new therapeutics, the last 
WHO classification of CNS tumors from year 2016 brought about some changes (Table 1) [7].
Demarcation of glioma borders is a subject of comprehensive research, considering that it is 
difficult to clearly define the line between tumor and healthy brain tissue macroscopically or 
with today available imaging techniques like functional MRI (fMRI), positron emission tomog-
raphy (PET), spectroscopy, and diffusion tensor imaging (DTI) [6, 17, 24]. Contemporary neu-
rophysiology plays a very important role in guidance of brain tumor surgery [17]. For tumors 
located in proximity to critical functional areas, the use of intraoperative electrostimulation 
Figure 1. Overall survival in the glioma molecular groups based on 1p/19q, IDH, and TERT promoter mutations in 
tumors (taken from Eckel-Passow et al. [21]).
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mapping (IEM) during awake craniotomy helps to maximize the extent of resection and to 
minimize the risk of permanent neurological morbidity, allowing a substantial increase in the 
survival and quality of life of patients [14, 17, 25].
5. Is there hope
Primary brain tumors remain hard and challenging work despite the progress in understand-
ing their genetics and technological progress that enabled safe and extensive tumor resection 
[3, 15, 17]. As gliomas include a variety of different histological tumor types and malignancy 
grades, contemporary achievements in terms of molecular imaging have given us a unique 
Other astrocytic tumors (often referred as “circumscribed 
gliomas”)
WHO I
• Pilocytic astrocytoma
WHO II
• Pleomorphic xanthoastrocytoma
WHO III
• Anaplastic pleomorphic xanthoastrocytoma
Diffuse astrocytic and oligodendroglial tumors (often 
referred as “diffuse gliomas”)
WHO II
• Diffuse astrocytoma, IDH-mutant
• Diffuse astrocytoma, IDH-wild type
• Diffuse astrocytoma, NOS
• Oligodendroglioma, IDH-mutant and 1p/19q-codeleted†
• Oligodendroglioma, NOS
WHO III (anaplastic)
• Anaplastic astrocytoma, IDH-mutant
• Anaplastic astrocytoma, IDH-wild type
• Anaplastic astrocytoma, NOS
• Anaplastic oligodendroglioma, IDH-mutant and 
1p/19q-codeleted
• Anaplastic oligodendroglioma, NOS
WHO IV
• Glioblastoma, IDH-wild type
• Glioblastoma, IDH-mutant
• Glioblastoma, NOS
• Diffuse midline glioma, H3 K27M-mutant
Ependymal tumors
WHO I
• Subependymoma
• Myxopapillary ependymoma
• WHO II
• Ependymoma
WHO II or III
• Ependymoma, RELA fusion-positive
• WHO III
• Anaplastic ependymoma
Neuronal and mixed neuronal-glial tumors
• Diffuse leptomeningeal glioneuronal tumor
WHO I
• Dysembryoplastic neuroepithelial tumor
• Ganglioglioma
• Gangliocytoma
• Dysplastic gangliocytoma of cerebellum 
(Lhermitte-Duclos)
WHO III
• Anaplastic ganglioglioma
IDH, isocitrate dehydrogenase; NOS, not otherwise specified; RELA, reticuloendotheliosis viral oncogene homolog A [7]. 
† The last WHO classification of CNS tumors brought about some changes based on molecular findings.
Table 1. Simplified and modified from WHO 2016 classification of neuroepithelial tissue tumors.
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chance for a comprehensive interdisciplinary assessment of the glioma pathophysiology, 
with direct implications in terms of the medical and surgical treatment strategies available for 
patients [26]. The concept of individualized surgery in brain tumor neurosurgery, that is, spe-
cifically in neurooncology of glial tumors is actually based on the goal to provide as radical 
tumor resection as possible, without causing (additional) neurological deficit (Figure 2) [27].
Unfortunately, the prognosis of patients with grade IV malignant glioma particularly recur-
rent is dismal, and there is currently no effective therapy, but there are some promising 
agents as vaccine immunotherapy or recombinant nonpathogenic poliorhinovirus chimera 
(PVSRIPO) [28, 29]. Desjardins et al. have recently reported that overall survival among the 
patients who received PVSRIPO immunotherapy was higher at 24 and 36 months than the 
rate among controls [29]. Extension of surgical excision is still an important predictor of out-
come. Achieving a gross total resection of the tumor without significant complication requires 
a thorough understanding of available surgical approaches [15, 17, 30–32]. For majority of 
those patients, short-course radiotherapy with concurrent and adjuvant TMZ will bring a 
benefit, while gain from bevacizumab is limited [13]. There have been some ideas that certain 
antiepileptics also have a favorable effect on the outcome with glioma patients, but these stud-
ies have not given affirmative results [33]. To provide a highly personalized medicine, we will 
also have to make additional effort toward molecular neuropathology [30].
What do we want to see in the future? A patient from the supposed risk group will be scanned 
with MRI spectroscopy, 7T MRI, or similar MRI prototype. At the level of a robot medical 
center, needle biopsy of tumor will be performed, which will be followed by oncogenomic 
characterization of lesion, with gene map reading and defining. Research in the field of stem 
cells also has an important place and implications in the future. By way of stem cells, a specific 
Figure 2. Contrast-enhanced axial T1 MRI scan of 54-year-old female patient with IDH-mutant glioblastoma. (A) 
Preoperative MRI and (B) 4 years after extensive surgical resection, followed with TMZ and radiotherapy treatment. 
Small part of recurrent tumor is visible 50 months after initial resection. Patient is still without any neurological deficit.
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medicine will be produced, individualized for the particular patient, and in a microcapsule, it 
will be implanted into the brain zone affected by tumor, by way of robot surgery and injection 
needle. These are not at all unrealistic expectations in the next decade or two. Perhaps a bit 
futuristic, but it is also realistic to expect vaccination against glioma [28], that is, specific repair 
stem cells that will recognize the “glioma-damaged” part of the brain and thus preventively 
work on it, before the growth of tumor itself.
It is not too much to expect that the current generation of neurooncologists will resolve glioma 
problem for ever. We should bravely carry on. Time is brain.
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